BioDuro announced that it established a joint venture with Cenra API Solutions, also as known as Chunghwa Chemical Synthesis & Biotech Co. The joint venture aims to combine the services of the CRDMO and a pharmaceutical chemical manufacturer. They hope to add significant commercial-scale active pharmaceutical ingredient (API) manufacturing capacity at Cenra’s campus in Taipei, Taiwan,…

Novo Nordisk today announced plans to invest €432 million ($507 million) in its facility in Monksland, Athlone, Ireland. The Danish pharmaceutical giant plans to add significant additional manufacturing capacity for current and future GLP-1 treatments. According to Novo Nordisk, the expansion of the tabletting facility further reinforces its long-term commitment to Ireland and global healthcare…

Novartis announced today that it plans to establish a new radioligand therapy (RLT) manufacturing site in Denton, Texas. The purpose-built RLT site will mark Novartis’ fifth in the U.S. and first manufacturing facility in Texas. It comes as part of a planned $23 billion investment across the U.S. Novartis has, in the past couple of…

ERWEKA is highlighting its Digital Dissolution Offline System for the DT 950 and DT 9510 series, an integrated offline sampling solution designed to automate dissolution workflows while maintaining pharmacopoeia compliance on existing DT platforms. The system pairs guided digital control with modular hardware to help QC labs reduce manual handling and improve consistency. The solution…

Bora Pharmaceuticals and GSK announced today that they entered into a $250 million agreement to renew a five-year manufacturing partnership. In 2020, Bora purchased a facility in Mississauga, Ontario, from GSK, Now, they say the renewed collaboration reinforces their long-standing relationship and expands their partnership. It also provides GSK access to multiple sites within the…

AbbVie (NYSE:ABBV) today announced plans to invest $380 million in two new active pharmaceutical ingredient (API) manufacturing facilities. The investment comes at the company’s current North Chicago, Illinois, campus. With it, the company plans to add new, state-of-the-art facilities to integrate advanced manufacturing technologies with AI to support the production of its next-generation neuroscience and…

Healthcare CDMO manufacturer MGS has brought a 300,000 square foot drug delivery device manufacturing facility online in Richfield, Wisconsin. The move expands U.S. production capacity as demand for complex combination products strains available cleanroom capacity . FDA approved a record number of combination products in recent years, and the 505(b)(2) pathway has made device-drug combos…

Johnson & Johnson (NYSE:JNJ) announced today that it plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The new facility will further expand the company’s U.S. manufacturing capacity as it looks to advance its portfolio and pipeline of medicines for cancer, immune-mediated and neurological diseases. J&J…

Fujifilm Biotechnologies recently celebrated the grand opening of its expanded biopharmaceutical CDMO facility in Teesside, U.K. In a Feb. 11 news release, the company said the expansion introduces 2,000 L and 5,000 L single-use bioreactors with a total capacity up to 19,000 L. The goal is to provide small- and mid-scale antibody manufacturing, and there’s…

Pharmaceutical manufacturers don’t just need digitalization – they need speed. Traditional MES deployment timelines, often stretching from 8 to 24 months, hinder responsiveness and innovation. The process can feel long and arduous, as the challenge isn’t just building mission-critical systems, but also aligning requirements, collecting tribal knowledge, and validating every digital process under rigorous regulatory…